|
1
|
Arlauckas SP, Popov AV and Delikatny EJ:
Choline kinase alpha-putting the choK-hold on tumor metabolism.
Prog Lipid Res. 63:28–40. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sanchez-Lopez E, Zimmerman T, Gomez del
Pulgar T, Moyer MP, Lacal Sanjuan JC and Cebrian A: Choline kinase
inhibition induces exacerbated endoplasmic reticulum stress and
triggers apoptosis via CHOP in cancer cells. Cell Death Dis.
4:e9332013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chang CC, Few LL, Konrad M and See Too WC:
Phosphorylation of human choline kinase beta by protein kinase A:
Its impact on activity and inhibition. PLoS One. 11:e01547022016.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gruber J, See Too WC, Wong MT, Lavie A,
McSorley T and Konrad M: Balance of human choline kinase isoforms
is critical for cell cycle regulation: Implications for the
development of choline kinase-targeted cancer therapy. FEBS J.
279:1915–1928. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wu G and Vance DE: Choline kinase and its
function. Biochem Cell Biol. 88:559–564. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gómez-Pérez V, McSorley T, See Too WC,
Konrad M and Campos JM: Novel 4-amino bis-pyridinium and
bis-quinolinium derivatives as choline kinase inhibitors with
antiproliferative activity against the human breast cancer SKBR-3
cell line. ChemMedChem. 7:663–669. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gebert LFR and MacRae IJ: Regulation of
microRNA function in animals. Nat Rev Mol Cell Biol. 20:21–37.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hirschberger S, Hinske LC and Kreth S:
miRNAs: Dynamic regulators of immune cell functions in inflammation
and cancer. Cancer Lett. 431:11–21. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lan H, Lu H, Wang X and Jin H: MicroRNAs
as potential biomarkers in cancer: Opportunities and challenges.
Biomed Res Int. 2015:1250942015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Xu H, Hu YW, Zhao JY, Hu XM, Li SF, Wang
YC, Gao JJ, Sha YH, Kang CM, Lin L, et al: MicroRNA-195-5p acts as
an anti-oncogene by targeting PHF19 in hepatocellular carcinoma.
Oncol Rep. 34:175–182. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhao X, Dou W, He L, Liang S, Tie J, Liu
C, Li T, Lu Y, Mo P, Shi Y, et al: MicroRNA-7 functions as an
anti-metastatic microRNA in gastric cancer by targeting
insulin-like growth factor-1 receptor. Oncogene. 32:1363–1372.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bueno MJ, Gómez de Cedrón M, Gómez-López
G, Pérez de Castro I, Di Lisio L, Montes-Moreno S, Martínez N,
Guerrero M, Sánchez-Martínez R, Santos J, et al: Combinatorial
effects of microRNAs to suppress the Myc oncogenic pathway. Blood.
117:6255–6266. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kasinski AL, Kelnar K, Stahlhut C,
Orellana E, Zhao J, Shimer E, Dysart S, Chen X, Bader AG and Slack
FJ: A combinatorial microRNA therapeutics approach to suppressing
non-small cell lung cancer. Oncogene. 34:3547–3555. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
van Rooij E, Purcell AL and Levin AA:
Developing microRNA therapeutics. Circ Res. 110:496–507. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chakraborty C, Sharma AR, Sharma G, George
C, Doss CGP and Lee SS: Therapeutic miRNA and siRNA: Moving from
bench to clinic as next generation medicine. Mol Ther Nucleic Acid.
8:132–143. 2017. View Article : Google Scholar
|
|
16
|
Broderick JA and Zamore PD: MicroRNA
therapeutics. Gene Ther. 18:1104–1110. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Betel D, Koppal A, Agius P, Sander C and
Leslie C: Comprehensive modeling of microRNA targets predicts
functional non-conserved and non-canonical sites. Genome Biol.
11:R902010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lorenz WA and Clote P: Computing the
partition function for kinetically trapped RNA secondary
structures. PLoS One. 6:e161782011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zuker M: Mfold web server for nucleic acid
folding and hybridization prediction. Nucleic Acids Res.
31:3406–3415. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Xayaphoummine A, Bucher T and Isambert H:
Kinefold web server for RNA/DNA folding path and structure
prediction including pseudoknots and knots. Nucleic Acids Res.
33:(Web Server Issue). W605–W610. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Friedman RC, Farh KK, Burge CB and Bartel
DP: Most mammalian mRNAs are conserved targets of microRNAs. Genome
Res. 19:92–105. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Granata A, Nicoletti R, Tinaglia V, De
Cecco L, Pisanu ME, Ricci A, Podo F, Canevari S, Iorio E, Bagnoli M
and Mezzanzanica D: Choline kinase-alpha by regulating cell
aggressiveness and drug sensitivity is a potential druggable target
for ovarian cancer. Br J Cancer. 110:330–340. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Mariotto E, Viola G, Ronca R, Persano L,
Aveic S, Bhujwalla ZM, Mori N, Accordi B, Serafin V, López-Cara LC
and Bortolozzi R: Choline kinase alpha inhibition by EB-3D triggers
cellular senescence, reduces tumor growth and metastatic
dissemination in breast cancer. Cancers (Basel). 10:3912018.
View Article : Google Scholar
|
|
25
|
Oliveira AC, Bovolenta LA, Nachtigall PG,
Herkenhoff ME, Lemke N and Pinhal D: Combining results from
distinct MicroRNA target prediction tools enhances the performance
of analyses. Front Genet. 8:592017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zheng Z, Reichel M, Deveson I, Wong G, Li
J and Millar AA: Target RNA secondary structure is a major
determinant of miR159 efficacy. Plant Physiol. 174:1764–1778. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Rosa A and Brivanlou AH: Regulatory
non-coding RNAs in pluripotent stem cells. Int J Mol Sci.
14:14346–14373. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Xu J, Lin H, Li G, Sun Y, Chen J, Shi L,
Cai X and Chang C: The miR-367-3p increases sorafenib chemotherapy
efficacy to suppress hepatocellular carcinoma metastasis through
altering the androgen receptor signals. EBioMedicine. 12:55–67.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Xiao G, Gao X, Sun X, Yang C, Zhang B, Sun
R, Huang G, Li X, Liu J, Du N, et al: miR-367 promotes tumor growth
by inhibiting FBXW7 in NSCLC. Oncol Rep. 38:1190–1198. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yan W, Jiang X, Wang G, Li W, Zhai C, Chen
S, Shang F, Zhao Z and Yu W: Cyto-biological effects of
microRNA-424-5p on human colorectal cancer cells. Oncol Lett.
20:1202020. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chen N, Chon HS, Xiong Y, Marchion DC,
Judson PL, Hakam A, Gonzalez-Bosquet J, Permuth-Wey J, Wenham RM,
Apte SM, et al: Human cancer cell line microRNAs associated with in
vitro sensitivity to paclitaxel. Oncol Rep. 31:376–383. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Bin Z, Dedong H, Xiangjie F, Hongwei X and
Qinghui Y: The microRNA-367 inhibits the invasion and metastasis of
gastric cancer by directly repressing Rab23. Genet Test Mol
Biomarkers. 19:69–74. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Guan Y, Chen L, Bao Y, Qiu B, Pang C, Cui
R and Wang Y: High miR-196a and low miR-367 cooperatively correlate
with unfavorable prognosis of high-grade glioma. Int J Clin Exp
Pathol. 8:6576–6588. 2015.PubMed/NCBI
|
|
34
|
Campayo M, Navarro A, Vinõlas N, Diaz T,
Tejero R, Gimferrer JM, Molins L, Cabanas ML, Ramirez J, Monzo M
and Marrades R: Low miR-145 and high miR-367 are associated with
unfavourable prognosis in resected nonsmall cell lung cancer. Eur
Respir J. 41:1172–1178. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhu Z, Xu Y, Zhao J, Liu Q, Feng W, Fan J
and Wang P: miR-367 promotes epithelial-to-mesenchymal transition
and invasion of pancreatic ductal adenocarcinoma cells by targeting
the Smad7-TGF-β signalling pathway. Br J Cancer. 112:1367–1375.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Taipaleenmäki H, Browne G, Akech J, Zustin
J, van Wijnen AJ, Stein JL, Hesse E, Stein GS and Lian JB:
Targeting of Runx2 by miR-135 and miR-203 impairs progression of
breast cancer and metastatic bone disease. Cancer Res.
75:1433–1444. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Li C, Penet MF, Wildes F, Takagi T, Chen
Z, Winnard PT, Artemov D and Bhujwalla ZM: Nanoplex delivery of
siRNA and prodrug enzyme for multimodality image-guided molecular
pathway targeted cancer therapy. ACS Nano. 4:6707–6716. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Chen Z, Krishnamachary B and Bhujwalla ZM:
Degradable dextran nanopolymer as a carrier for choline kinase
(Chok) siRNA cancer therapy. Nanomaterials (Basel). 6:342016.
View Article : Google Scholar
|
|
39
|
Rupaimoole R and Slack FJ: MicroRNA
therapeutics: Towards a new era for the management of cancer and
other diseases. Nat Rev Drug Discov. 16:203–222. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Falcon SC, Hudson CS, Huang Y, Mortimore
M, Golec JM, Charlton PA, Weber P and Sundaram H: A non-catalytic
role of choline kinase alpha is important in promoting cancer cell
survival. Oncogenesis. 2:e382013. View Article : Google Scholar : PubMed/NCBI
|
